首页 › 基金 › Timothy G. Youngquist 2020 Irrevocable Trust › CHRS

Timothy G. Youngquist 2020 Irrevocable Trust 对 CHRS 的持仓历史

COHERUS ONCOLOGY INC · 医疗保健

Timothy G. Youngquist 2020 Irrevocable Trust 在 Q3 2026 的 13F 申报中披露持有 CHRS(COHERUS ONCOLOGY INC)13,050,623 股,市值约 US$15.8M,约占其申报组合的 3.22%,在其申报持仓中市值排名第 4 位。 Timothy G. Youngquist 2020 Irrevocable Trust 最近 4 个申报季度中有 4 个季度披露了 CHRS 持仓,最早可追溯至 Q4 2025。

最新持仓 (Q3 2026)13.05M 股
申报持仓市值$15.79M
组合权重3.22%
首次申报Q4 2025
最近变动增持
更新于2026-10-15

最后更新: 2026-10-15 · 来源: SEC EDGAR Form 13F-HR

Timothy G. Youngquist 2020 Irrevocable Trust 对 CHRS 的持仓演变

Timothy G. Youngquist 2020 Irrevocable Trust 于 Q4 2025 首次披露 CHRS 持仓:5,895,349 股(约 US$8.4M)。 该持仓在 Q3 2026 达到峰值 13,050,623 股,市值约 US$15.8M。 在 4 次申报中,Timothy G. Youngquist 2020 Irrevocable Trust 1 次增持、2 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 13,050,623 股、市值约 US$15.8M,环比增持 12,850,623 股。。 持仓曾出现大幅变动:Q1 2026 减持约 92% (随后一个季度股价下跌 17%)、Q2 2026 减持约 57% (随后一个季度股价下跌 14%)、Q3 2026 增持约 6425% (随后一个季度股价下跌 33%)。

逐季持仓明细

季度股数金额变化
Q4 2025 5.90M $8.37M 新进
Q1 2026 460.00K $75.00K 减持
Q2 2026 200.00K $25.00K 减持
Q3 2026 13.05M $15.79M 增持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 CHRS 与 13F 数据

CHRS(COHERUS ONCOLOGY INC)属于医疗保健行业。我们追踪的基金中还有 20 只申报持有 CHRS,申报仓位最大的包括:Samsara BioCapital, LLC (US$4.8M), Kohlberg Kravis Roberts & Co. L.P. (US$4.2M), CM Management, LLC (US$2.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 CHRS 的基金

查看 CHRS 的全部基金持有人 →

常见问题

How long has Timothy G. Youngquist 2020 Irrevocable Trust held CHRS?

Timothy G. Youngquist 2020 Irrevocable Trust has disclosed CHRS holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Timothy G. Youngquist 2020 Irrevocable Trust's current position in CHRS?

As of Q3 2026, Timothy G. Youngquist 2020 Irrevocable Trust holds 13.05M shares of CHRS (COHERUS ONCOLOGY INC), valued at $15.79M, representing 3.22% of its reported portfolio and ranking #4.

Has Timothy G. Youngquist 2020 Irrevocable Trust been buying or selling CHRS?

In the latest 13F filing (Q3 2026), Timothy G. Youngquist 2020 Irrevocable Trust increased its position in CHRS. The position peaked in Q3 2026 at 13.05M shares.

Which other funds hold CHRS?

Other major institutional holders of CHRS include Samsara BioCapital, LLC, Kohlberg Kravis Roberts & Co. L.P., CM Management, LLC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.